{'fraction_non_alphanumeric': 0.03526550466153223, 'fraction_numerical': 0.03445480340494528, 'mean_word_length': 5.108910891089109, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The safety of electronic cross‐match in patients with warm autoantibodies

Warm autoantibodies (WA) are directed against individuals’ own red blood cell (RBC) antigens. Warm autoantibodies can interfere with and complicate investigations for the detection and identification of RBC alloantibodies [1]. The safety of the electronic cross-match was investigated when the presence of clinically significant red cell alloantibodies was excluded in the setting of completely or incompletely absorbed warm autoantibodies. The serologic evaluations of 60 subjects with warm autoantibodies and no evidence of clinically significant red cell all antibodies were evaluated from 3 March 2002 through September 2005. Outcomes evaluated were: acute haemolytic transfusion reactions (AHTR), delayed haemolytic transfusion reactions (DHTR); and newly identified clinically significant red cell alloantibodies. The control group consisted of ageand gender-matched transfused patients with a negative type and screen. The Poisson distribution was assumed for data analysis. Three hundred forty-seven transfusion events were analysed. The total number of transfusion days was 128 in study subjects and 393 in controls. The median number of RBC transfusions per study subject was 2 (range: 1 to 9 transfusions) and 2 per control subject (range: 1 to 95 transfusions). The median follow-up period was 3 days for study subjects (range: 0 to 1181 days) and 10 days for controls (range: 0 to 858 days). Study subjects received a total of 339 RBC units with a median of 4 per subject (range: 1 to 29 units). The incidence of AHTR was 0/128 transfusion days [95% confidence interval (CI); 0–2·9/100 transfusion days]. The incidence of DHTR was 0/100 person years (95% CI; 0–20·1/100 person years). Only two study subjects were alloimmunized. Anti-E was identified in both cases with an incidence of 10·9/100 person years (95% CI; 1·3–39·2/100 person years). There was no significant difference in the rate of AHTR between the study group and control groups. The results also suggest similar rates for DHTR and red cell alloantibody formation in the two groups. We conclude that the electronic cross-match is safe for patients with warm autoantibodies and no evidence of clinically significant RBC alloantibodies. Furthermore, the use of the electronic cross-match in this setting will avoid the problem of issuing units labelled as incompatible when a serologic cross-match technique is used.